Back to top
more

NovoCure Limited (NVCR)

(Delayed Data from NSDQ)

$12.34 USD

12.34
1,315,567

+0.29 (2.36%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $12.36 +0.02 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for NVCR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for NovoCure Limited falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 912 970 939 854 328
Receivables 84 112 111 118 88
Notes Receivable 0 0 0 0 0
Inventories 38 29 24 27 24
Other Current Assets 0 0 0 0 0
Total Current Assets 1,034 1,112 1,074 999 440
Net Property & Equipment 63 45 36 23 17
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 14 11 12 11 5
Total Assets 1,146 1,192 1,140 1,052 479
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 94 85 73 54 37
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 85 74 70 60 49
Total Current Liabilities 179 159 143 114 86
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 3 6 12 8
Convertible Debt 0 0 0 0 0
Long-Term Debt 569 566 562 430 149
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 8 5 5 6 4
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 784 750 729 575 262
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,353 1,222 1,100 1,111 871
Retained Earnings -986 -778 -686 -631 -651
Other Equity -5 -2 -3 -4 -3
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 363 441 410 477 218
Total Liabilities & Shareholder's Equity 1,146 1,192 1,140 1,052 479
Total Common Equity 363 441 410 477 218
Shares Outstanding 106.80 104.90 103.80 101.80 98.90
Book Value Per Share 3.39 4.21 3.95 4.68 2.20

Fiscal Year End for NovoCure Limited falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 912 923 941 959
Receivables NA 84 88 91 99
Notes Receivable NA 0 0 0 0
Inventories NA 38 37 33 32
Other Current Assets NA 0 0 0 0
Total Current Assets NA 1,034 1,048 1,065 1,089
Net Property & Equipment NA 63 57 53 49
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 14 12 15 11
Total Assets NA 1,146 1,146 1,159 1,174
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 94 80 83 81
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 85 77 68 67
Total Current Liabilities NA 179 157 150 149
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 1 2
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 569 568 567 566
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 5 5 5
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 784 753 743 742
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,353 1,334 1,307 1,266
Retained Earnings NA -986 -938 -889 -832
Other Equity NA -5 -2 -2 -3
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 363 394 416 432
Total Liabilities & Shareholder's Equity NA 1,146 1,146 1,159 1,174
Total Common Equity 0 363 394 416 432
Shares Outstanding 107.00 106.80 106.80 106.60 106.20
Book Value Per Share 0.00 3.39 3.69 3.90 4.07